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Prognostic value of multiple
repeated biomarkers in
pulmonary arterial
hypertension associated with
congenital heart disease
Pulmonary arterial hypertension (PAH) is
a well-recognized complication of congen-
ital heart disease (CHD), associated with
alarmingly high morbidity and mortality.1
PAH-CHD is considered a complex syn-
drome involving many pathophysiological
mechanisms, the components of which can
be represented by various biomarkers.
There has been a growing interest in
biomarkers as prognostic markers in chronic
heart disease, given the wide availability and
reproducibility, non-invasive nature and low
costs. Although a wide variety of biomark-
ers have been explored in PAH-CHD,2,3
only natriuretic peptides have been incor-
porated by the European guidelines.4 The
use of multiple biomarkers in combination
(the so-called ‘multimarker’ approach) may
however be of greater prognostic value
than a single biomarker approach. More-
over, little is known about the prognostic
value of repeatedly measured biomarkers.
Ideally, changes in biomarker levels over
time should reflect disease progression more
accurately. We therefore evaluated the prog-
nostic value of repeated measurements of
several biomarkers in a prospective cohort
of patients with PAH-CHD. Pathways and
corresponding candidate biomarkers studied
were (i) myocardial stress [N-terminal pro
brain natriuretic peptide (NT-proBNP)],
(ii) myocyte injury [high-sensitive troponin
T (hs-TnT)], (iii) cardio-renal dysfunction
(cystatin-C) and (iv) extracellular matrix
remodelling (galectin-3).
This observational dual-centre study
included consecutive PAH-CHD adults who
were prospectively followed at our institu-
tions with first clinical assessment between
January 2004 and January 2016. According to
local protocol, patients underwent routine
evaluation every 6–12months at outpa-
tient clinics, including regular assessment
of serum biomarkers using commercially
available immunoassays. The endpoint was
all-cause mortality. Patient deaths and causes
of death were site determined and verified by
medical records documentation. Biomarker
levels were log-transformed and expressed
as one standard deviation (SD) increase for
hazard ratios (HRs) and 95% confidence
intervals (CIs). The association with mortality
was assessed using fitted mixed-effect, Cox
regression and joint models, adjusted for age,
gender and Eisenmenger syndrome (ES).
The study cohort consisted of 98 patients
(43±16 years, 34% male, 37% Down syn-
drome), of whom 90% was treatment naive
at baseline and started on advanced therapy
within 1month [interquartile range (IQR)
0.4–4.0]. The majority of patients had ES
(69%), followed by closed defects (17%),
systemic-to-pulmonary shunts (12%), and
small defects (1%). Among ES patients, 47%
had complex anatomy, 29% post-tricuspid
shunts, and 24% pre-tricuspid shunts. During
a median follow-up of 6.9 (IQR 4.1–10.7)
years, 41 patients (42%) died. Half of ES
patients (47%) died at 50± 12 years, whereas
patients with systemic-to-pulmonary shunts
(50%), closed defects (12%) or small defects
(100%) died at older age (60±16, 66± 16,
and 77 years, respectively). Causes of death
were validated in 38 (93%) cases, and primar-
ily due to right heart failure (49%) and sudden
cardiac death (12%). The average number of
repeated measurements per patient during
follow-up was nine for NT-proBNP, five
for hs-TnT, and four for cystatin-C and
galectin-3. Corresponding median levels of
repeated measurements were: NT-proBNP
518 ng/L (IQR 223–1433), hs-TnT 11 ng/L
(IQR 5–24), cystatin-C 0.97mg/L (IQR
0.81–1.23), and galectin-3 15𝜇g/L (IQR
12–18). The correlations among the four
biomarkers were weak to moderate (all
r< 0.4). All biomarker levels in patients who
died progressively increased before time of
death compared to those who remained
alive during follow-up. Initiation of advanced
therapy reduced biomarker levels in short-
term, although levels deteriorated again after
1 year.5
After imputation and internal valida-
tion with 40 bootstrap samples, baseline
levels were associated with an increased
risk of death, HRs as follows: NT-proBNP
1.90 (95% CI 1.30–2.78); hs-TnT 1.54
(95% CI 1.14–2.08); cystatin-C 1.69 (95%
CI 1.21–2.37); galectin-3 1.58 (95% CI
1.12–2.19). During follow-up, one SD
increase in biomarker level represented 250%
increase of NT-proBNP, 150% of hs-TnT, and
50% of cystatin-C and galectin-3. Each SD
increase in biomarker level was associated
with a doubled risk of death at any particular
time (all P< 0.001), adjusted HRs as follows:
NT-proBNP 2.17 (95%CI 1.64–2.89); hs-TnT
2.34 (95% CI 1.61–3.41); cystatin-C 1.81
(95% CI 1.35–2.43); galectin-3 1.79 (95% CI
1.27–2.74). Risk prediction with repeated
measurements was more accurate than with
single measurements. Figure 1 illustrates the
improved prognostic accuracy for an individ-
ual patient with NT-proBNP measurements;
95% CI is significantly broader using only the
last single measurement compared with using
repeated measurements. Of potential clinical
value to physicians, we developed a free online
risk stratification tool: https://biomarkers-
pah-chd.shinyapps.io/PAH-CHDbiomarkers/.
Of the four biomarkers, NT-proBNP, hs-TnT
and cystatin-C achieved excellent predictive
performance for 10-year mortality (c-index
0.81–0.92), whereas galectin-3 did not
(c-index 0.60). In combination, the three
strongest biomarkers, however, did not fur-
ther improve discriminatory abilities (c-index
0.85).
We evaluated the prognostic value of a
range of repeated biomarkers, individually
and collectively, in patients with PAH-CHD.
Our patient cohort had a high mortality rate,
with 42% deceased by the end of follow-up.
All repeated biomarkers individually were
powerful predictors of mortality risk: patients
with one SD increase had more than doubled
the risk of death compared to those with
no or less elevation. This is consistent with
what has been found in previous studies in
acquired heart failure6,7 that have shown that
serial measures provide superior prognostic
power over a single biomarker measurement.
Previous studies have suggested using abso-
lute cut-off values.6 From a clinical point of
view, this approach may however neglect,
at least to some extent, changes within a
subject and not serve individual patients
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Dynamic survival predictions for an individual patient based on single (A) vs. repeated (B) N-terminal pro brain natriuretic peptide
(NT-proBNP) measurements. (A) The probability that this patient will survive for the next 3 years after the last observed time (dotted vertical
line) for which a longitudinal measurement (dot) was available is 45%, with wide 95% confidence interval (shading). (B) The survival probability
of the same patient for the same next 3 years after the last observed time is only 18% based on the complete repeated biomarker history (dots),
with narrower 95% confidence interval (shading). (JM package, R Project for Statistical Computing, Vienna, Austria). Online risk stratification
tool: https://biomarkers-pah-chd.shinyapps.io/PAH-CHDbiomarkers/.
optimally. Based on our findings, we rec-
ommend to make use of relative changes
(e.g. 100% increase) derived from our study
rather than absolute (e.g. > 400 ng/L) change
criterion, as this could help to initiate a
more tailored approach. Altogether, it high-
lights the importance of serial measures in
chronic diseases, in which multiple underlying
pathophysiological mechanisms are ongoing
dynamic processes that cannot be captured
by a single biomarker measure at one point
in time. Similar to data from acquired heart
failure studies, NT-proBNP and hs-TnT were
the most powerful prognostic biomarkers in
our cohort. Contrary to studies in acquired
heart failure,8 we did not find a prognostic
gain of using multiple repeated biomarkers
compared to individual repeated biomarkers.
The following limitations of our study
should be considered. It is a dual-centre study
with relatively small sample size. There is
potential for information bias given that the
number of measurements was not equal for
all biomarkers. The study focused on a panel
of four biomarkers. Therefore, additional
studies will be necessary to evaluate other
markers of different pathways in PAH-CHD
and validate our results in clinically distinct
cohorts. Further research should certainly
determine the optimal frequency of mea-
surements required and investigate whether
individual changes in biomarkers over time
can also reflect response to therapy. This
will enable further optimization of individual
follow-up strategies and timely initiation of
therapeutic management.
In conclusion, repeated biomarker
measurements were associated with an
approximately two-fold higher mortality risk
per SD increase and were more powerful
predictors of mortality than single measure-
ments. A multimarker approach provided
no incremental prognostic value beyond
the repeated measurements of individual
biomarkers. Therefore, our findings support
the concept of regular assessment of at
least one biomarker, e.g. NT-proBNP, to
help identify patients with PAH-CHD at
greatest risk.
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